Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$241.6 million.

  • NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders fell 332.54% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.54% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders stood at -$241.6 million, which was down 36.54% from -$176.9 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders' 5-year high stood at -$6.6 million during FY2020, with a 5-year trough of -$241.6 million in FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$166.1 million, with a median of -$176.9 million in 2023.
  • Data for NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders shows a maximum YoY crashed of 415.60% (in 2021) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders (Yearly) stood at -$6.6 million in 2020, then crashed by 415.60% to -$33.8 million in 2021, then tumbled by 135.29% to -$79.6 million in 2022, then plummeted by 122.19% to -$176.9 million in 2023, then plummeted by 36.54% to -$241.6 million in 2024.